Marburg I polymorphism of factor VII-activating protease is associated with idiopathic venous thromboembolism.
The factor VII-activating protease (FSAP) variant Marburg I is known to attenuate the profibrinolytic system in vitro and was recently shown to be a significant predictor for the evolution and progression of carotid stenosis. The objective of this case-control study was to assess FSAP Marburg I's role in the occurrence of venous thromboembolism (VTE). The frequency of FSAP Marburg I was significantly increased in patients with a history of VTE (17 of 213 patients, 8.0%, P = .014) or idiopathic VTE (12 of 103 patients, 11.7%, P = .002) compared to healthy controls (5 of 213 controls, 2.3%). Logistic regression analysis confirmed FSAP Marburg I to be an independent risk factor for VTE (odds ratio, 3.5; 95% confidence interval [CI], 1.2-10.0) and idiopathic VTE (odds ratio, 6.2; 95% CI, 2.0-18.9).
Institutee of Transfusion Meidicine, Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany. berthold.hoppe@charite.de
Berthold
B
Hoppe
Farzaneh
F
Tolou
Hartmut
H
Radtke
Holger
H
Kiesewetter
Thomas
T
Dörner
Abdulgabar
A
Salama
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D005260:Female; D005787:Gene Frequency; D006801:Humans; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D015995:Prevalence; D012307:Risk Factors; D012697:Serine Endopeptidases / Q000235:genetics* / Q000502:physiology; D013923:Thromboembolism / Q000201:enzymology / Q000453:epidemiology / Q000235:genetics*; D020246:Venous Thrombosis / Q000201:enzymology / Q000453:epidemiology / Q000235:genetics*
C433550:HABP2 protein, human; D012697:Serine Endopeptidases